Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 3NIH 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, Follicular 3Breast Neoplasms 3Waldenstrom Macroglobulinemia 2Recurrence 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell, Marginal Zone 2Colorectal Neoplasms 2Virus Diseases 1Unspecified Adult Solid Tumor, Protocol Specific 1Pregnancy Related 1Pancreatic Neoplasms 1Neuroblastoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia 1Glioma 1Glioblastoma 1Epstein-Barr Virus Infections 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

Cyclophosphamide 176Rituximab 164fludarabine phosphate 97Peripheral Blood Stem Cell Transplantation 95Filgrastim 73Etoposide 67Radiotherapy 63Mycophenolic Acid 62Whole-Body Irradiation 58Tacrolimus 49Melphalan 49Cyclosporine 49Busulfan 47Lenalidomide 45Antilymphocyte Serum 39Vincristine 37Prednisone 37Cytarabine 37fludarabine 35Methotrexate 33Carmustine 32obinutuzumab 31Doxorubicin 30Bendamustine Hydrochloride 30Methylprednisolone 27ibritumomab tiuxetan 25Cord Blood Stem Cell Transplantation 25sargramostim 24Bortezomib 24Granulocyte Colony-Stimulating Factor 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Follicular × Antibodies, Monoclonal × Clear all
NCT06550141 2025-11-14

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Massachusetts General Hospital

Phase 2 Recruiting
28 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05073250 2023-05-12

IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.

Chinese PLA General Hospital

Phase 2 Unknown
40 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT00989586 2017-02-06

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1/2 Completed
35 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡